No Data
Jiangsu Hengrui Pharmaceuticals (600276.SH): The injection SHR-1681 has received the drug clinical trial approval notification.
On December 20, Gelonghui reported that Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiaries, Shanghai Shengdi Pharmaceutical Co., Ltd. and Suzhou Shengdiya Biomedical Co., Ltd., received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration for the injectable SHR-1681, and clinical trials will begin soon. The injectable SHR-1681 is a Class I therapeutic Biological Product independently developed by the company, which can specifically bind to certain antigens on the surface of tumor cells, and then be endocytosed into the cells and transported to lysosomes to kill tumor cells.
Jiangsu Hengrui Medicine Gets China Green Light for Bladder Cancer Drug Combo
Hengrui Medicine's Unit Included In Chinese Drug Administration's Breakthrough Therapy Drug List
Jiangsu Hengrui Pharmaceuticals (600276.SH): Injection Rycan-Cumab has been included in the proposed list of breakthrough treatment varieties.
On December 16, Gelonghui reported that Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary, Suzhou Shengdiya Biomedical Co., Ltd., has had its injectable recombinant trastuzumab (SHR-A1811) included in the proposed list of breakthrough therapy varieties by the National Medical Products Administration's Drug Review Center, with a publication period of 7 days. In addition, this product has already received breakthrough therapy designation for six indications. The injectable recombinant trastuzumab can bind to and be internalized by HER2-expressing tumor cells, releasing toxins via proteolytic cleavage in the tumor cell lysosome, inducing cell cycle arrest and subsequently inducing apoptosis in tumor cells.
Jiangsu Hengrui Pharmaceuticals (600276.SH): SHR-2173 injection has received the drug clinical trial approval notice.
On December 13, Glonghui reported that Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary, Guangdong Hengrui Pharmaceuticals Co., Ltd., has received the approval notice for clinical trials of SHR-2173 injection issued by the National Medical Products Administration and will begin clinical trials shortly. SHR-2173 injection is a self-developed Biological Product by the company that targets abnormally activated immune cells to exert anti-inflammatory and immune-suppressing biological effects, potentially reducing the levels of autoantibodies and improving the disease activity status of LN patients, providing new treatment options for patients.
Research Reports on the gold mine丨China Securities Co.,Ltd.: Jiangsu Hengrui Pharmaceuticals plans to initiate Listed in Hong Kong listing, accelerating international transformation, maintaining a "Buy" rating.
The Research Reports from CSC indicate that Jiangsu Hengrui Pharmaceuticals (600276.SH) plans to conduct an IPO in Hong Kong, which is expected to significantly promote the dual-driven strategy of technology innovation and internationalization, further supporting the development of the company's international business. At the same time, the company's innovative research and development continue to advance, with multiple data readouts for Innovative Drugs, and several progress made in overseas applications and authorizations. Future attention can be focused on: 18 NDA pipelines expected to be approved for market launch between Q4 2024 and 2025; data disclosure at academic conferences; potential overseas expansion and business development, etc.; and continuous volume growth of products after the implementation of medical insurance in 2025. Considering that the company's Innovative Drugs have good growth potential.
Shareholders in Jiangsu Hengrui Medicine (SHSE:600276) Are in the Red If They Invested Three Years Ago
